| Immunotherapies for hepatocellular carcinoma JM Llovet, F Castet, M Heikenwalder, MK Maini, V Mazzaferro, DJ Pinato, ... Nature reviews Clinical oncology 19 (3), 151-172, 2022 | 791 | 2022 |
| NASH limits anti-tumour surveillance in immunotherapy-treated HCC D Pfister, NG Núñez, R Pinyol, O Govaere, M Pinter, M Szydlowska, ... Nature 592 (7854), 450-456, 2021 | 771 | 2021 |
| Association of prior antibiotic treatment with survival and response to immune checkpoint inhibitor therapy in patients with cancer DJ Pinato, S Howlett, D Ottaviani, H Urus, A Patel, T Mineo, C Brock, ... JAMA oncology 5 (12), 1774-1778, 2019 | 471 | 2019 |
| A novel, externally validated inflammation-based prognostic algorithm in hepatocellular carcinoma: the prognostic nutritional index (PNI) DJ Pinato, BV North, R Sharma British journal of cancer 106 (8), 1439-1445, 2012 | 431 | 2012 |
| The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinoma DJ Pinato, R Sharma, E Allara, C Yen, T Arizumi, K Kubota, D Bettinger, ... Journal of hepatology 66 (2), 338-346, 2017 | 346 | 2017 |
| PD-L1 A Kythreotou, A Siddique, FA Mauri, M Bower, DJ Pinato Journal of clinical pathology 71 (3), 189-194, 2018 | 292 | 2018 |
| A novel and validated prognostic index in hepatocellular carcinoma: the inflammation based index (IBI) DJ Pinato, J Stebbing, M Ishizuka, SA Khan, HS Wasan, BV North, ... Journal of hepatology 57 (5), 1013-1020, 2012 | 191 | 2012 |
| Prognostic performance of inflammation-based prognostic indices in primary operable non-small cell lung cancer DJ Pinato, RJ Shiner, MJ Seckl, J Stebbing, R Sharma, FA Mauri British journal of cancer 110 (8), 1930-1935, 2014 | 185 | 2014 |
| Immune-based therapies for hepatocellular carcinoma DJ Pinato, N Guerra, P Fessas, R Murphy, T Mineo, FA Mauri, ... Oncogene 39 (18), 3620-3637, 2020 | 184 | 2020 |
| Inflammation-based prognostic indices in malignant pleural mesothelioma DJ Pinato, FA Mauri, R Ramakrishnan, L Wahab, T Lloyd, R Sharma Journal of Thoracic Oncology 7 (3), 587-594, 2012 | 168 | 2012 |
| Clinical portrait of the SARS-CoV-2 epidemic in European patients with cancer DJ Pinato, A Zambelli, J Aguilar-Company, M Bower, CCT Sng, R Salazar, ... Cancer discovery 10 (10), 1465-1474, 2020 | 167 | 2020 |
| Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice A Cortellini, M Tucci, V Adamo, LS Stucci, A Russo, ET Tanda, ... Journal for immunotherapy of cancer 8 (2), 2020 | 159 | 2020 |
| Immune checkpoint inhibitor therapy in patients with preexisting inflammatory bowel disease H Abu-Sbeih, DM Faleck, B Ricciuti, RB Mendelsohn, AR Naqash, ... Journal of Clinical Oncology 38 (6), 576, 2020 | 154 | 2020 |
| Challenges and opportunities in the clinical development of STING agonists for cancer immunotherapy L Motedayen Aval, JE Pease, R Sharma, DJ Pinato Journal of clinical medicine 9 (10), 3323, 2020 | 152 | 2020 |
| Prognosis of patients with hepatocellular carcinoma treated with immunotherapy–development and validation of the CRAFITY score B Scheiner, K Pomej, MM Kirstein, F Hucke, F Finkelmeier, O Waidmann, ... Journal of hepatology 76 (2), 353-363, 2022 | 150 | 2022 |
| Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child‐Pugh A and B cirrhosis: a real‐world study A D’Alessio, CAM Fulgenzi, N Nishida, M Schönlein, J von Felden, ... Hepatology 76 (4), 1000-1012, 2022 | 138 | 2022 |
| A pilot randomized, placebo controlled, double blind phase I trial of the novel SIRT1 activator SRT2104 in elderly volunteers V Libri, AP Brown, G Gambarota, J Haddad, GS Shields, H Dawes, ... PloS one 7 (12), e51395, 2012 | 127 | 2012 |
| Matrix stiffness modulates the activity of MMP-9 and TIMP-1 in hepatic stellate cells to perpetuate fibrosis D Lachowski, E Cortes, A Rice, D Pinato, K Rombouts, ... Scientific reports 9 (1), 7299, 2019 | 122 | 2019 |
| Long-term sequelae are highly prevalent one year after hospitalization for severe COVID-19 M Bellan, A Baricich, F Patrucco, P Zeppegno, C Gramaglia, PE Balbo, ... Scientific reports 11 (1), 22666, 2021 | 115 | 2021 |
| Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective … DJ Pinato, J Tabernero, M Bower, L Scotti, M Patel, E Colomba, S Dolly, ... The Lancet Oncology 22 (12), 1669-1680, 2021 | 108 | 2021 |
